Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AATF
REST API REST API
Homo sapiens
AATF is differentially expressed in 243 experiments: 89 organism parts: blood, cervix, ... (87 more);, 171 disease states: normal, adenocarcinoma, ... (169 more);, 71 cell types 249 cell lines 25 compound treatments and 67 other conditions.
Synonyms CHE-1, DED, CHE1
Orthologs Aatf (Mus musculus)   aatf (Danio rerio)   AATF_CHICK (Gallus gallus)   BFR2 (Saccharomyces cerevisiae)   AATF (Bos taurus)   Aatf (Rattus norvegicus)   CG11188 (Drosophila melanogaster)   aatf (Xenopus laevis)   AATF (Canis familiaris)   (Compare orthologs)
Gene Ontology Term focal adhesion, cytosol, protein binding, apoptosis, ribosome biogenesis, cytoplasm, embryonic cleavage, transcription, DNA-dependent, Golgi apparatus, protein domain specific binding, anti-apoptosis, regulation of mitotic cell cycle, cell adhesion, positive regulation of transcription from RNA polymerase II promoter, centrosome, nucleus, response to DNA damage stimulus, positive regulation of transcription, DNA-dependent, nucleolus, negative regulation of superoxide anion generation, leucine zipper domain binding, negative regulation of amyloid precursor protein biosynthetic process, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, tau protein binding, sequence-specific DNA binding transcription factor activity, negative regulation of reactive oxygen species metabolic process
InterPro Term TRAUB
UniProt Accession Q9NY61
Search EB-eye ENSG00000108270
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
SW480
1
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
Raji
2
E-GEOD-96, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
243 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (37 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
CXCR5(lo)ICOS(int) CD4 T cell
1
E-MEXP-750
CD34+ progenitor cell
1
E-GEOD-96
PTCL
1
E-GEOD-19069
monolayer
1
E-GEOD-4219
pro B cell
1
E-MEXP-1403
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-62, E-MEXP-1331, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lymphoma
2
E-MTAB-62, E-MTAB-37
prostate cancer
2
E-MTAB-62, E-GEOD-6919
165 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
none
1
5
E-GEOD-5824, E-MEXP-1601, E-GEOD-412, E-TABM-868, E-TABM-782, ... (6 experiments)
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
bacterial endotoxin
1
1
E-GEOD-3284
HMB-PP (phosphoantigen)
1
E-MEXP-1601
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
19 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
29
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-22593, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-6434, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1422, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-2466

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.338 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM